DNMT3A and myelodysplastic syndrome: Results from phase II clinical trials confirmed that canakinumab is safe and effectively targets IL-1β signaling, and yielded durable response in LR-MDS patients with single somatic driver mutation in TET2 or DNMT3A [256, 257].